The deal was initially announced in August, but federal law required the companies to allow a 30-day waiting period to elapse before proceeding. The waiting period expired Sept. 27 without any objections from the Federal Trade Commission.
Under the terms of the deal, Barr's subsidiary Duramed will purchase Shire's attention-deficit/hyperactivity disorder treatment Adderall for $63 million. Duramed will re-launch Adderall in the quarter ending Dec. 31, 2006.
Costly malfunction causes beer flood at Boston-area brewery
Wisconsin business offering 'therapeutic cuddling' forced to close